Cargando…
Inpatient Use of Metformin and Acarbose Is Associated with Reduced Mortality of COVID-19 Patients with Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is a strong risk factor for complications of coronavirus disease 2019 (COVID-19). The effect of T2DM medications on COVID-19 outcomes remains unclear. In a retrospective analysis of a cohort of 131 patients with T2DM hospitalized for COVID-19 in Wuhan, we have previou...
Autores principales: | Li, Willis, Li, Jinghong, Wei, Qi, McCowen, Karen, Xiong, Wei, Liu, Jiao, Jiang, Wenlijun, Thomas, Robert, Hepokoski, Mark, He, Ming, Shyy, John, Malhotra, Atul, Xiong, Nian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010742/ https://www.ncbi.nlm.nih.gov/pubmed/33791691 http://dx.doi.org/10.21203/rs.3.rs-287308/v1 |
Ejemplares similares
-
Inpatient use of metformin and acarbose is associated with reduced mortality of COVID‐19 patients with type 2 diabetes mellitus
por: Li, Jinghong, et al.
Publicado: (2021) -
Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19
por: Li, Jinghong, et al.
Publicado: (2020) -
ACE2, Metformin, and COVID-19
por: Malhotra, Atul, et al.
Publicado: (2020) -
Comparison of adjunctive therapy with metformin and acarbose in patients with Type-1 diabetes mellitus
por: Ziaee, Amir, et al.
Publicado: (2017) -
Evaluation of the pharmacokinetics of metformin and acarbose in the common marmoset
por: Fernandez, Elizabeth, et al.
Publicado: (2019)